CD4+CD126low/− Foxp3+ Cell Population Represents a Superior Subset of Regulatory T Cells in Treating Autoimmune Diseases

Ye Chen,Zhenjian Xu,Rongzhen Liang,Julie Wang,Anping Xu,Ning Na,Bin Li,Ruoning Wang,Miller Joseph,Nancy Olsen,Willa Hsueh,Song Guo Zheng
DOI: https://doi.org/10.1016/j.ymthe.2020.07.020
IF: 12.91
2020-11-01
Molecular Therapy
Abstract:CD4<sup>+</sup>Foxp3<sup>+</sup> regulatory T (Treg) cells are crucial for maintaining homeostasis and preventing autoimmune diseases. Nonetheless, we and others have previously reported that natural Treg cells are unstable and dysfunctional in the inflamed environment with a high-salt diet, limiting the Treg function in disease control. In this study, we made an innovative observation showing a high degree of heterogeneity within the Treg pool. We identified that CD126, interleukin (IL)-6 receptor alpha chain, contributed to Treg cell instability. Using a series of in vitro and in vivo experimental approaches, we demonstrated that CD126<sup>Lo/-</sup> Treg cells presented greater function and were more stable than CD126<sup>Hi</sup> nTreg cells, even in the presence of IL-6 and inflammation. Blockade of programmed death-1 (PD-1) interrupted CD126<sup>Lo/-</sup> nTreg cell stability. Additionally, CD126<sup>Lo/-</sup> Treg cells can treat colitis and established collagen-induced arthritis, while the CD126<sup>Hi</sup> cell population failed to do this. Moreover, we noted that CD126 expression of Treg cells had a positive correlation to rheumatoid arthritis (RA) severity and the stability of Treg cells. Our results strongly suggest that the manipulation of CD126<sup>Lo/-</sup> nTreg cells could be a novel strategy for the treatment of autoimmune diseases and for other conditions associated with a deficit of Treg cells.
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
What problem does this paper attempt to address?